Stereotaxis Inc. logo

Stereotaxis Inc. (STXS)

Market Closed
17 Jul, 20:00
AMEX AMEX
$
1. 55
-0.1
-6.0606%
$
160.29M Market Cap
- P/E Ratio
- Div Yield
5.68M Volume
-0.23 Eps
$ 1.65
Previous Close
Add Transaction
Day Range
1.48 1.88
Year Range
1.46 3.59
Want to track STXS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

STXS closed yesterday lower at $1.55, a decrease of -6.0606% from Thursday's close, completing a monthly decrease of -19.6891% or -$0.38. Over the past 12 months, STXS stock lost -33.1897%.
STXS is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0.0567%. On average, the company has surpassed earnings expectations by 0.0356%, based on the last three reports.
Stereotaxis Inc. has completed 2 stock splits, with the recent split occurring on Nov 04, 2013.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on AMEX (USD).

STXS Chart

People also search for

InfuSystem Holdings Inc.
$ 8.92
-3.4632%
Intest Corporation
$ 13.44
-2.3256%
Cleancore Solutions Inc.
$ 0.6
-1.634%
WYY
WidePoint Corporation
$ 11.66
-4.5827%
MRT
Marti Technologies Inc.
$ 1.6
+1.9108%
Stereotaxis Q1 Earnings Call Highlights

Stereotaxis Q1 Earnings Call Highlights

Stereotaxis NYSEAMERICAN: STXS said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system.

Marketbeat | 2 months ago
Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.

Zacks | 2 months ago

Stereotaxis Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
GH
George Henning PACIFIC GLOBAL INVESTMENT MANAGEMENT Co.
18,900 $37,880 $30,429 -$7,451 -19.67%
BG
Bart Gancher Intech Investment Management LLC
16,768 $31,186.28 $26,912.64 -$4,273.64 -13.7%
Joseph Castro
Joseph Castro Nuveen LLC
73,990 $130,222 $120,233.75 -$9,988.25 -7.67%
SK
Samira Kadam Cherry Creek Investment Advisors Inc.
36,216 $92,756.45 $58,851 -$33,905.45 -36.55%
Bobby Adusumilli
Bobby Adusumilli SJS Investment Consulting Inc.
2 $3.68 $3.23 -$0.45 -12.23%

Stereotaxis Inc. (STXS) FAQ

What is the stock price today?

The current price is $1.55.

On which exchange is it traded?

Stereotaxis Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is STXS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 160.29M.

Has Stereotaxis Inc. ever had a stock split?

Stereotaxis Inc. had 2 splits and the recent split was on Nov 04, 2013.

Stereotaxis Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
David L. Fischel CEO
AMEX Exchange
85916J409 CUSIP
US Country
131 Employees
- Last Dividend
4 Nov 2013 Last Split
12 Aug 2004 IPO Date

Overview

Stereotaxis, Inc. is a pioneering company in the field of robotic systems, specializing in the design, manufacture, and marketing of advanced robotics, instruments, and information systems geared towards the interventional laboratory sector. Operating both in the United States and internationally, the company's cutting-edge technology primarily serves the purpose of enhancing the precision and safety of complex interventional procedures. Through its innovative solutions, Stereotaxis aims to facilitate physicians in navigating and manipulating devices within the human body with an unprecedented level of control and accuracy. Founded in 1990 and headquartered in Saint Louis, Missouri, Stereotaxis has established a strong reputation for its contribution to minimally invasive medical procedures, particularly in the realm of cardiology. The company’s commitment to innovation is also reflected in its strategic collaborations, such as with MAGiC catheter for cardiac ablation procedures, further emphasizing its role in advancing medical technology.

Products and Services

  • Robotic Magnetic Navigation (RMN) Systems – Including the Genesis RMN and Niobe systems, these platforms represent the core of Stereotaxis' offerings. They facilitate the image-guided delivery of catheters and guidewires through blood vessels and heart chambers directly to the sites requiring treatment, enabling physicians to perform complex interventional procedures with enhanced precision and safety.
  • Odyssey Information Solution – This comprehensive solution empowers hospitals and clinics to manage, control, record, and share interventional procedures in real-time across networks. The Odyssey platform is designed to streamline procedural workflows and enhance collaboration among medical professionals, irrespective of their physical location.
  • Stereotaxis Imaging Model S X-Ray System – As part of its offering for a fully robotic interventional operating room, this single-plane, full-power x-ray system includes a c-arm, powered table, motorized boom, and monitors. It's optimized to work seamlessly with Stereotaxis’ robotic systems, providing clear and precise imaging during procedures.
  • Disposables and Accessories – Among these, QuikCAS automated catheter advancement disposables stand out for their capability to advance electrophysiology catheters remotely, enhancing the efficiency and safety of cardiac interventions.
  • Vdrive System – This system enhances the navigation and stability of diagnostic and therapeutic devices during interventional procedures. By improving the control over these devices, Vdrive contributes to the overall precision and success of interventions.
  • V-Loop, V-Sono, and V-CAS Disposables – These components are designed to work with the Vdrive system, providing specific functionalities such as loop creation, ultrasound navigation, and catheter stability during interventional procedures. Each is developed to alleviate common challenges faced during complex medical interventions, thereby improving outcomes and patient safety.

Contact Information

Address: 710 North Tucker Boulevard
Phone: 314 678 6100